江阴贝瑞森制药

Berrisen Pharmaceutical is a Chinese biotechnology company specializing in the development and manufacture of marine-derived biomaterials for clinical use. Founded in 2011 by Dr. Gu Ming, the company focuses on high-purity chitosan technology to create advanced medical devices for wound care, dermatology, and gynecology. Their product portfolio includes Class II and Class III medical devices such as chitosan-based dressings, gels, and sprays designed to promote tissue repair and provide antimicrobial protection. Berrisen operates a state-of-the-art GMP manufacturing facility in Jiangyin and has established itself as a leader in the application of marine biomaterials within the Chinese healthcare market. The company's research and development efforts are centered on the modification and functionalization of polysaccharides to address unmet needs in chronic wound management and skin barrier restoration.